Blue Trust Inc. Has $11.25 Million Stock Holdings in HCA Healthcare, Inc. $HCA

Blue Trust Inc. cut its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 11.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,384 shares of the company’s stock after selling 3,294 shares during the quarter. Blue Trust Inc.’s holdings in HCA Healthcare were worth $11,245,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in HCA Healthcare during the 2nd quarter valued at $1,152,408,000. Viking Global Investors LP grew its position in shares of HCA Healthcare by 58.5% in the second quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after purchasing an additional 690,773 shares during the last quarter. Nordea Investment Management AB lifted its holdings in HCA Healthcare by 6.8% during the 2nd quarter. Nordea Investment Management AB now owns 927,781 shares of the company’s stock worth $350,404,000 after purchasing an additional 59,163 shares during the last quarter. Pacer Advisors Inc. grew its holdings in HCA Healthcare by 6,115.3% in the 3rd quarter. Pacer Advisors Inc. now owns 911,096 shares of the company’s stock valued at $388,309,000 after buying an additional 896,437 shares in the last quarter. Finally, LSV Asset Management lifted its holdings in shares of HCA Healthcare by 0.4% during the second quarter. LSV Asset Management now owns 868,849 shares of the company’s stock worth $332,856,000 after buying an additional 3,396 shares in the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, EVP Michael R. Mcalevey sold 3,892 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the transaction, the executive vice president owned 3,487 shares in the company, valued at $1,652,105.73. This trade represents a 52.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.30% of the company’s stock.

HCA Healthcare Stock Performance

HCA stock opened at $474.06 on Friday. HCA Healthcare, Inc. has a fifty-two week low of $289.98 and a fifty-two week high of $520.00. The stock has a fifty day moving average of $474.62 and a 200-day moving average of $419.32. The company has a market capitalization of $108.18 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 1.40 and a beta of 1.36.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, October 24th. The company reported $6.96 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $1.32. The firm had revenue of $19.16 billion during the quarter, compared to analyst estimates of $18.55 billion. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business earned $4.90 earnings per share. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. Equities analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 29th. Stockholders of record on Monday, December 15th will be given a $0.72 dividend. The ex-dividend date is Monday, December 15th. This represents a $2.88 annualized dividend and a dividend yield of 0.6%. HCA Healthcare’s payout ratio is 11.13%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HCA. Barclays raised their target price on shares of HCA Healthcare from $445.00 to $494.00 and gave the stock an “overweight” rating in a report on Monday, October 27th. Wall Street Zen upgraded HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Oppenheimer lifted their price objective on HCA Healthcare from $400.00 to $500.00 and gave the stock an “outperform” rating in a research note on Monday, October 27th. Bank of America increased their price target on HCA Healthcare from $430.00 to $470.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Finally, KeyCorp lifted their price target on shares of HCA Healthcare from $465.00 to $475.00 and gave the company an “overweight” rating in a research report on Monday, October 27th. Fourteen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $479.00.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.